Palmoplantar Keratoderma Market Report 2026

The palmoplantar keratoderma market size has grown steadily in recent years. It will grow from $0.88 billion in 2025 to $0.92 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increase in rare dermatological disorder diagnosis, growth in dermatology specialty clinics, expansion of retinoid therapies, rising patient awareness of genetic skin diseases, improved dermatopathology testing.

The palmoplantar keratoderma market size is expected to see strong growth in the next few years. It will grow to $1.13 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to growth in targeted dermatology drugs, expansion of genetic screening access, rising biologic therapy adoption, increase in specialty dermatology pipelines, broader orphan disease support programs. Major trends in the forecast period include targeted biologic skin therapies, advanced genetic diagnostic panels, long acting topical formulations, combination retinoid treatment protocols, home based phototherapy adoption.

The increasing prevalence of genetic mutations is anticipated to drive the growth of the palmoplantar keratoderma market in the coming years. Genetic mutations are alterations or variations in DNA sequences that can elevate susceptibility to hereditary conditions and dermatological disorders. The prevalence of genetic mutations is rising due to advancements in genomic sequencing and widespread genetic testing, which are enabling the detection and identification of a growing number of previously unrecognized DNA variations across populations. Rising genetic mutations contribute to palmoplantar keratoderma by expanding the population with inherited skin-gene alterations, resulting in earlier detection and a greater demand for targeted management. For example, in January 2023, according to a report published by the National Center for Biotechnology Information (NCBI), a division of the US-based National Library of Medicine (NLM), with approximately 140 million babies born each year, roughly 9.8 billion new human mutations are introduced into the gene pool annually. Therefore, the increasing prevalence of genetic mutations is propelling the growth of the palmoplantar keratoderma market.

The rising healthcare expenditure is expected to drive the growth of the palmoplantar keratoderma market in the coming years. Healthcare expenditure refers to the total financial resources allocated for health services, including medical treatments, diagnostic procedures, medications, and preventive care. Healthcare expenditure is increasing due to population aging, as older populations have higher rates of chronic diseases, require more frequent medical care, and often need long-term treatments, thereby raising overall healthcare costs. Rising healthcare expenditure supports palmoplantar keratoderma by enhancing access to specialized care, funding advanced diagnostics and therapies, and enabling timely, personalized treatment for patients. For example, in January 2026, according to the Centers for Medicare & Medicaid Services, a US-based government agency, in 2024, national health expenditure (NHE) increased by 7.2% to $5.3 trillion, averaging $15,474 per person and representing 18% of GDP, while Medicare spending rose by 7.8% to $1.11 trillion, accounting for 21% of total NHE. Therefore, rising healthcare expenditure is propelling the growth of the palmoplantar keratoderma market.

Organizations operating in the palmoplantar keratoderma market are focusing on conducting clinical trials to develop innovative drugs such as TRPV3 inhibitors to provide targeted, disease-modifying treatments that go beyond symptomatic relief. TRPV3 inhibitors are drugs that block the TRPV3 ion channel, helping to normalize skin cell growth, strengthen the skin barrier, and reduce pain and thickening associated with palmoplantar keratoderma. For example, in June 2024, Kamari Pharma Ltd., a clinical-stage biotechnology company, launched KM-001, a topical TRPV3 inhibitor, following promising Phase 1b clinical results. KM-001 is formulated as a cream applied twice daily and has demonstrated high safety with no severe adverse events, along with an overall responder rate of 87% in patients with pachyonychia congenita and punctate palmoplantar keratoderma type 1. Its unique mechanism helps normalize skin cell proliferation, enhance epidermal barrier formation, and reduce pain in affected patients, offering a disease-modifying alternative to conventional treatments. Kamari Pharma plans to advance KM-001 into Phase 2 trials while also developing KM-023, an oral TRPV3 inhibitor, for broader keratoderma indications.

Major companies operating in the palmoplantar keratoderma market are LEO Pharma, Krystal Biotech Inc., and Kamari Pharma.

Tariffs on imported dermatology drugs, specialty chemicals, and phototherapy equipment are increasing treatment costs in the palmoplantar keratoderma market. Drug based therapy segments and light therapy equipment are most affected by cross border duties. Regions dependent on imported specialty dermatology products face higher patient pricing. These pressures can slow adoption of advanced therapies in smaller clinics. At the same time, tariffs are encouraging local formulation and regional specialty drug manufacturing.

The palmoplantar keratoderma market research report is one of a series of new reports that provides palmoplantar keratoderma market statistics, including palmoplantar keratoderma industry global market size, regional shares, competitors with a palmoplantar keratoderma market share, detailed palmoplantar keratoderma market segments, market trends and opportunities, and any further data you may need to thrive in the palmoplantar keratoderma industry. This palmoplantar keratoderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Palmoplantar keratoderma (PPK) refers to a set of rare dermatological conditions characterized by thickened skin on the palms and soles. The disorder can be hereditary or acquired and often necessitates long-term management via topical therapies, systemic medications, or biologic treatments to alleviate skin thickening, inflammation, and associated discomfort.

The primary types of palmoplantar keratoderma treatment include topical treatments, systemic treatments, phototherapy, and surgical interventions. Topical treatments refer to medications and therapeutic formulations applied directly to the skin to control hyperkeratosis, minimize scaling, and relieve associated symptoms. These conditions are classified by type including non-lamellar keratoderma, lamellar keratoderma, epidermolytic keratoderma, and palmoplantar keratoderma with systemic involvement. Diagnostic approaches include clinical examination, histopathological analysis, and genetic testing. They are applied across patient groups including pediatric and adult populations and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The palmoplantar keratoderma market consists of revenues earned by entities by providing services such as clinical consultations and dermatological assessments, genetic and diagnostic testing, prescription management, phototherapy sessions, and surgical evaluation and interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The palmoplantar keratoderma market also includes sales of oral retinoids, keratolytic agents, immunomodulators, corticosteroids, and adjunctive systemic therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.